Загрузка...
Clinical Trials for Disease-Modifying Therapies in Alzheimer’s Disease: A Primer, Lessons Learned, and a Blueprint for the Future(1)
Alzheimer’s disease (AD) has no currently approved disease-modifying therapies (DMTs), and treatments to prevent, delay the onset, or slow the progression are urgently needed. A delay of 5 years if available by 2025 would decrease the total number of patients with AD by 50% in 2050. To meet the defi...
Сохранить в:
| Опубликовано в: : | J Alzheimers Dis |
|---|---|
| Главные авторы: | , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
IOS Press
2018
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6004914/ https://ncbi.nlm.nih.gov/pubmed/29562511 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3233/JAD-179901 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|